GT Biopharma (FRA:OXIA) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

GT Biopharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:OXIA vs CTXR, HIND, ZIVO: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, GT Biopharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GT Biopharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Margin of Safety % (DCF FCF Based) falls into.


FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price